GARDP, WHO, ICMR to col­lab­o­rate for study­ing sep­sis & AMR

BioSpectrum (India) - - POLICY AND REGULATORY NEWS -

Global An­tibi­otic Re­search and De­vel­op­ment Part­ner­ship (GARDP), the World Health Or­ga­ni­za­tion (WHO) and In­dian Coun­cil of Med­i­cal Re­search (ICMR) re­cently or­gan­ised an event on re­duc­ing neona­tal and child mor­tal­ity by ad­dress­ing drug re­sis­tance through col­lab­o­ra­tion, re­search, and in­no­va­tion. More than 80 re­searchers from 11 coun­tries met in New Delhi to kick off an ob­ser­va­tional study to un­der­stand sep­sis in new­borns and cur­rent an­tibi­otic pre­scrib­ing prac­tices. This is part of the GARDP’s broader pro­gramme to de­velop new and im­proved an­tibi­otic treat­ments for new­borns. The ob­ser­va­tional study, led by the GARDP, is ben­e­fit­ing from $2 mil­lion fund­ing from Bill & Melinda Gates Foun­da­tion to sup­port study sites in Bangladesh, In­dia, Kenya, South Africa, and Uganda. The study will gen­er­ate a ro­bust ev­i­dence base on how neona­tal sep­sis is man­aged which can be used as a ba­sis for eval­u­at­ing fu­ture in­ter­ven­tions in neonates. Out­comes of in­ter­est will in­clude mor­tal­ity, an­tibi­otic use, and du­ra­tion of an­timi­cro­bial ther­apy.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.